ArticleScientific reports2021

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.

I Blancas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.